Posted by Michael Wonder on 14 Jul 2022
NICE recommends Piqray and Trodelvy, maintaining 100% approvals of breast cancer drugs since 2018
14 July 2022 - An agreement with the companies on the price of two breast cancer treatments, Piqray and Trodelvy, has paved the way for NICE to be able to make them available immediately to around 3,450 people on the NHS and maintaining NICE’s 100% approval rate of breast cancer drugs since 2018.
In final draft guidance published today NICE has recommended Piqray (alpelisib, Novartis), used with the hormonal therapy fulvestrant, for treating hormone receptor positive, HER2 negative, PIK3CA mutated locally advanced or metastatic breast cancer that has grown after treatment with combined hormonal therapy and a cancer growth inhibitor.
